Related Experiment Videos
Pharmacokinetics of cefotaxime and desacetylcefotaxime in the young
1Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, USA.
Insights
Cefotaxime (CTX) and its metabolite (dCTX) pharmacokinetics change significantly in the first year of life due to developing renal function. Age-specific data allows for individualized CTX dosing regimens in pediatric patients.
Area of Science:
- Pharmacology
- Pediatric Nephrology
- Drug Metabolism and Disposition
Background:
- The pharmacokinetics of cefotaxime (CTX) and its primary metabolite, desacetylcefotaxime (dCTX), are known to vary with patient development.
- Significant alterations in drug disposition are observed during early life, particularly within the first year.
Purpose of the Study:
- To analyze the developmental impact on cefotaxime and desacetylcefotaxime pharmacokinetics.
- To establish the basis for individualizing cefotaxime dosing strategies in pediatric populations.
Main Methods:
- Review of available pharmacokinetic data for cefotaxime and desacetylcefotaxime in developing individuals.
- Correlation of pharmacokinetic changes with the maturation of renal function, including glomerular filtration and tubular secretion.
Main Results:
- Pharmacokinetic disposition of CTX and dCTX is significantly influenced by developmental stage, with major shifts occurring within the first year of life.
- The acquisition of mature renal function is a primary driver of these pharmacokinetic changes during infancy.
Conclusions:
- Age-appropriate pharmacokinetic data for CTX and dCTX are crucial for tailoring dosing regimens to individual pediatric patients.
- Justification exists for the development and implementation of alternative, safe, and effective dosing strategies based on developmental pharmacokinetics.
Abstract:
Available information on the pharmacokinetics of cefotaxime (CTX) and desacetylcefotaxime (dCTX) indicates that their disposition depends on development, with the greatest changes occurring during the 1st year of life. To a great extent, these changes reside with the acquisition of renal function (e.g., both glomerular filtration and active tubular secretion) during the 1st year of life. When the impact of development on CTX and dCTX disposition is considered, it is apparent that age-appropriate pharmacokinetic data can be used to individualize CTX dosing regimens according to age. Also, alternative dosing regimens that have been proven to be both safe and effective can be justified.